715 related articles for article (PubMed ID: 21115743)
21. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
22. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
[TBL] [Abstract][Full Text] [Related]
25. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
26. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.
Sarma K; Margueron R; Ivanov A; Pirrotta V; Reinberg D
Mol Cell Biol; 2008 Apr; 28(8):2718-31. PubMed ID: 18285464
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.
Qiu JJ; Lin YY; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Gynecol Oncol; 2014 Jul; 134(1):121-8. PubMed ID: 24662839
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
[TBL] [Abstract][Full Text] [Related]
30. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
31. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
Balasubramanian S; Adhikary G; Eckert RL
Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
[TBL] [Abstract][Full Text] [Related]
32. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract][Full Text] [Related]
33. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
34. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
Rizzo S; Hersey JM; Mellor P; Dai W; Santos-Silva A; Liber D; Luk L; Titley I; Carden CP; Box G; Hudson DL; Kaye SB; Brown R
Mol Cancer Ther; 2011 Feb; 10(2):325-35. PubMed ID: 21216927
[TBL] [Abstract][Full Text] [Related]
35. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
[TBL] [Abstract][Full Text] [Related]
38. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
39. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Zhang Q; Padi SK; Tindall DJ; Guo B
Cell Death Dis; 2014 Oct; 5(10):e1486. PubMed ID: 25341040
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
